Back to top
more

Arbutus Biopharma (ABUS)

(Delayed Data from NSDQ)

$3.77 USD

3.77
387,202

+0.04 (1.07%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $3.76 -0.01 (-0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%

Intercept Pharmaceuticals, Inc. (ICPT) shares rose over 9% in the last trading session.

    Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data

    Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.

      NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session

      NewLink Genetics Corporation (NLNK) shares rose almost 10% in the last trading session.

        Alexion Soliris Fails in Phase II/III Delayed Graft Function Study

        Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.

          Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

          Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

            Celgene (CELG) Otezla Approved in Japan for Two Indications

            Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.

              Roche Presents Positive Follicular Lymphoma Data on Gazvya

              Roche Holding AG (RHHBY) announced encouraging data from the pivotal phase III study, GALLIUM.

                Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

                Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint

                  Indradip Ghosh headshot

                  New Strong Buy Stocks for December 5th

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                    Aimmune Closes Enrolment in Phase III Peanut Allergy Study

                    Aimmune Therapeutics, Inc. (AIMT) announced that it has completed global enrollment in the phase III PALISADE study on AR101

                      Foamix Completes Enrolment in Phase III Acne Drug Studies

                      Foamix Pharmaceuticals Ltd. (FOMX) announced that it has completed patient enrollment in two phase III studies

                        Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor

                        Valeant Pharmaceuticals International, Inc. (VRX) announced that it is expanding its sales force to reach primary care physicians.

                          Indradip Ghosh headshot

                          New Strong Buy Stocks for November 21st

                          Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday